This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Zacks.com featured highlights PagSeguro Digital, Affiliated Managers, Cigna, Barrett Business Services and Fidelis Insurance
by Zacks Equity Research
PagSeguro Digital, Affiliated Managers, Cigna, Barrett Business Services and Fidelis Insurance have been highlighted in this Screen of The Week article.
Are These 3 Beaten-Down S&P 500 Members Worth a Look?
by Derek Lewis
The market has enjoyed a fantastic run in 2024, building nicely on last year???s gains. But not all have joined the party, specifically these three. Deep in the red year-to-date, are they worth a look?
Why Elevance (ELV) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Elevance's (ELV) top line is poised to gain from rising product revenues, administrative fees and other revenues.
5 Low Price-to-Sales Stocks to Fetch Solid Portfolio Gains
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PAGS, AMG, CI, BBSI and FIHL hold promise.
Cigna Group (CI) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cigna (CI) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the most recent trading session, Cigna (CI) closed at $343.94, indicating a +0.49% shift from the previous trading day.
Elevance Health (ELV) Bolsters CarelonRx With Paragon Buyout
by Zacks Equity Research
The infusion services from Paragon Healthcare are expected to complement Elevance Health's (ELV) suite of pharmacy services.
An In-Depth Analysis of Encompass Health's (EHC) 2024 Outlook
by Zacks Equity Research
Growth in Medicare and Managed Care pricing, along with capacity additions of six de novos with 280 beds, will likely have an impact on Encompass Health's (EHC) 2024 bottom line.
Here's Why You Should Add Cigna (CI) Stock to Your Portfolio
by Zacks Equity Research
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.
The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics
by Zacks Equity Research
The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Molina (MOH) Up 2.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cigna (CI) Unveils Updated Long-Term Growth Targets & Solutions
by Zacks Equity Research
Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.
Centene (CNC) Up 3.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Centene (CNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ensign Group (ENSG) Up 30.8% in 6 Months: More Growth Ahead?
by Zacks Equity Research
Ensign Group's (ENSG) growing strength in its Skilled Services business is a major upside.
Wall Street Bulls Look Optimistic About Cigna (CI): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Cigna (CI) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
3 Top-Ranked Stocks to Buy for Stability
by Derek Lewis
Targeting low-beta stocks can provide a valuable layer of stability for portfolios. After all, defense wins ballgames.
HCA Healthcare (HCA) Rises 24.8% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare's (HCA) growing equivalent admissions are supporting performance.
The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers
by Zacks Equity Research
The Joint's (JYNT) fourth-quarter 2023 results are likely to reflect higher expenses and patient volumes.
5 Valuable Low Price-to-Sales Stocks to Refresh Your Portfolio
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like TAP, PAGS, CI, STT and FHN hold promise.
Centene (CNC), Pyx Health Unite to Treat Mental Health Issues
by Zacks Equity Research
Centene (CNC) partners with Pyx Health to address loneliness and mental health issues among the insured.
CI vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
If You Invested $1000 in Cigna a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Why Cigna (CI) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.